Literature DB >> 15663665

Thalidomide for dermatology: a review of clinical uses and adverse effects.

Inacio R Faver1, Samantha G Guerra, W P Daniel Su, Rokea el-Azhary.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15663665     DOI： 10.1111/j.1365-4632.2004.02445.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  4 in total

1.  Lenalidomide for refractory cutaneous manifestations of pediatric systemic lupus erythematosus.

Authors:  E Y Wu; L E Schanberg; E C Wershba; C E Rabinovich
Journal:  Lupus       Date:  2016-11-12       Impact factor: 2.911

Review 2.  Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience.

Authors:  Sarah A Holstein; Philip L McCarthy
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

3.  Community-acquired lung abscess caused by Legionella micdadei in a myeloma patient receiving thalidomide treatment.

Authors:  Louis P Girard; Daniel B Gregson
Journal:  J Clin Microbiol       Date:  2007-07-03       Impact factor: 5.948

4.  Rosai-Dorfman disease successfully treated with thalidomide.

Authors:  Edward Chen; Peter Pavlidakey; Naveed Sami
Journal:  JAAD Case Rep       Date:  2016-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.